T0	Participants 72 122	surgical patients with serious systemic infection.
T1	Participants 285 326	patients with serious systemic infection.
T2	Participants 327 430	Thirty-seven surgical patients were evaluated for efficacy and 46 patients were evaluated for toxicity.
T3	Participants 1639 1690	patients who have serious infections after surgery.